Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06388161 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine to Shen Chun-Hong
    • Primary completion date: Dec 31, 2025 to Dec 31, 2026
    • Collaborators shortened, about 13 words
    v2
  2. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
769 trials monitored
See 48 trials at risk
Seizure is one of the most common symptoms in autoimmune encephalitis with neuronal surface-mediated antibodies. Interestingly, some patients may exhibit new-onset seizures as the initial manifestation without fulminant sign of encephalitis, particularly in the early stage. It is essential to recognize these patients early and to perform antibody testing, as studies have reported early immunotherapy can improve their clinical outcomes. At the same time, it is important to limit the number of patients who require testing, for the sake of specificity and cost effectiveness. Thus, this prospective, multicenter study aims to identify neural antibodies in patients with focal seizures of unknown etiology, and to create a score to preselect patients requiring autoantibody testing.
Trial Details
NCT Number NCT06388161
Lead Sponsor Shen Chun-Hong
Conditions
(from sponsor)
Epilepsy, Encephalitis Autoimmune
Related terms Autoimmune Diseases of the Nervous System, Epilepsy
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov